Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Greer Receives FDA Approval To Begin Sublingual-Oral Immunotherapy Trial

By Pharmaceutical Processing | January 11, 2005

LENOIR, NC (January 10, 2005) — Greer Laboratories, Inc., a provider of allergy immunotherapy products and services, has received Food & Drug Administration (FDA) approval to begin Phase I safety and dosing studies focused on sublingual-oral administration of dust mite allergenic extracts.

Dust mite is one of the most prevalent allergens. Of the roughly 50 million people who suffer from allergies in the United States, approximately 15 percent are sensitive to the dust mite allergens. It is estimated that an additional 10 to 15 million people remain undiagnosed.

“The approval to move forward with our safety and dosing trials marks a major milestone for Greer’s R&D sublingual clinical program,” states Bob Esch, Ph.D, Greer chief scientist.

The World Health Organization now classifies allergy as the fourth most important disease in the world and estimates that by 2010, approximately 40 percent to 50 percent of the world’s population could be affected.

In the United States, approximately 3 million of the 50 million allergy sufferers are treated with predominantly subcutaneous immunotherapy. Sublingual immunotherapy is delivered via the patient’s oral mucosa.

“Sublingual immunotherapy is of interest to some allergists because it offers a potential alternative for patients who may not be treated with injection immunotherapy,” stated Dr. Spencer Atwater, former president of the Joint Council of Allergy, Asthma & Immunology

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE